You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameGalantamineProduct NameRAZADYNE®Therapeutic AreaBehaviors and Mental DisordersEnrollment974% Female54%% WhiteN/A
Product ClassAlzheimer's Disease - Cholinesterase InhibitorsSponsor Protocol NumberCR003145 // GAL-INT-11Data PartnerJohnson & JohnsonCondition StudiedAlzheimer DiseaseMean/Median Age (Years)70
Supporting Documentation
- Collected Datasets Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0352 : Deciphering AD Etiology: A Synthesis of Trial and Observational Data
- 2023-5195 : Predictive modeling of adverse events and symptoms patterns in large scale clinical trials
- 2022-5053 : Adverse events reported in association with APOE genotype during clinical trials
- 2021-4836 : Adverse events of acetylcholinesterase inhibitors - systematic review and meta-analysis of double-blind randomized controlled trials
- 2021-4743 : Machine Learning Approaches to Predicting Treatment Outcomes in Alzheimer's Disease
- 2021-4683 : The effects of systemic anti-infective concomitant medications on progression of neurological diseases
- 2020-4448 : Reanalysis of Alzheimer?s Disease Clinical Trials Using Longitudinal Latent Trait Models
- 2020-4323 : Identification of biomarkers associated with Alzheimer?s disease progression that correlate with responses to medications.
- 2017-1746 : Heterogeneity in relative treatment efficacy by age, sex, socioeconomic status and comorbidity
- 2016-0765 : Improving the statistical analysis of cognitive outcomes in randomised controlled trials: The ?Optimising the Analysis of Cognition? Collaboration